Increasing Medication Adherence Through Physician Incentives and Messaging

Medication Adherence Clinical Trial

Official title:

Increasing Medication Adherence Through Physician Incentives and Messaging

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01603329
• Other study ID #: 007
• Status: Completed
• Phase: N/A
• First received: May 16, 2012
• Last updated: October 22, 2015
• Start date: June 2012
• Est. completion date: March 2014

Study information

• Verified date: October 2015
• Source: National Bureau of Economic Research, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The goal of this project is to increase patient adherence to medication using communications and incentives for physicians. The investigators are partnering with a health insurance company, Humana Inc, to design and implement an incentives program for physicians whose patients increase their medication adherence for oral diabetes medication, hypertension (ACEI or ARB) medication, and/or cholesterol (statins) medication. The investigators will use behavioral economics to explore the best way to communicate the incentives to the physicians.

Description:

Traditional economics would suggest that the best way to maximize adherence would be to give physicians financial incentives to improve adherence to all relevant drugs, and that communications to physicians should emphasize all of the relevant drugs. Behavioral economics suggests theory suggests that if you emphasize everything, then you are effectively emphasizing nothing. Behavioral econonmics would suggest to maximize adherence one should give physicians financial incentives for improving adherence for a small number of relevant drugs, and communications to physicians should emphasize a small number of the relevant drugs. This allows physicians to focus their energy and reduces the probability that they will give up because they're overwhelmed, or in other words, avoid the phenomenon called metric fatigue.

Humana has already implemented an incentives program for physicians, and the investigators will work with them to design a program that just focuses on medication adherence. Physicians targeted for this pilot could also be enrolled in another Humana incentives program, but this incentives program will act independently of the other.

There are two treatment dimensions the investigators will test via random assignment at the practice level:

1. Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.

2. Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.

In a previous study to increase uptake of colonoscopies among employees at a partner firm, the investigators found that using a post it note to catch the attention of the employee statistically significantly increased colonoscopy uptake over a control group. The investigators will also employ an eye catching method in the proposed pilot. When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. They will be encouraged to include the patient sheet in their chart as a reminder to discuss medication adherence with their patient the next time they see them. For half of our arms, the investigators will make the patient sheets a bright, non-white, color, in order to futher draw the physicians' attention to that specific paper in their chart.

Our experimental arms will be:

1. Comprehensive incentives + comprehensive communication

2. Comprehensive incentives + comprehensive communication + printed on bright non-white paper

3. Focused incentives + focused communication (one for all three drug classes)

4. Focused incentives + focused communication + printed on bright non-white paper (one for all three drug classes)

5. Comprehensive communiation

6. Comprehensive communication + printed on bright non-white paper

7. Control arm: no communication + no incentives

The investigators hypothesize that physicians who receive focused incentives and focused communications will have more patients with increased medication adherence than physicians who receive comprehensive incentives and comprehensive communications. The investigators also hypothsize that physicians who receive patient sheets using bright, non-white paper will have more patients with increased medication adherence than physicians who receive plain white patient sheets.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 734
• Est. completion date: March 2014
• Est. primary completion date: February 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Physician in the Humana network

• Treats Humana Medicare Advantage Members

• Has Humana Medicare Advantage members who are taking at least one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and/or cholesterol (statins) medication, and who are less than 80% adherent.

Exclusion Criteria:

• Practices with more than 10 physicians

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Related Conditions & MeSH terms

• Medication Adherence

Intervention

Other:
• Increasing Medication Adherence through Physician Incentives and Messaging
There are two treatments: Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication. Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes. When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart.

Locations

Country	Name	City	State
United States	Humana, Inc	Louisville	Kentucky

Sponsors (2)

Lead Sponsor	Collaborator
National Bureau of Economic Research, Inc.	Humana, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Medication Adherence	The investigators will see how the treatment arms affect the targeted physicians' patients medication adherence for oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.	Up to two years	No
Secondary	Demographic Controls for Physicians	The investigators will see if our targeted physicians' demographic controls affect their patients' medication adherence rates before and after treatment.	Up to two years	No
Secondary	Demographic Controls for Patients	The investigators will see how demographic controls for patients affect our targeted physicians' patients' medication adherence.	Up to 2 years	No